RMD
ResMed Inc.
$231.49
장중 · Vol 104.3K · 52주 $180.27–$284.87 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $237.77 · Aug 31, 2026
RMD 가격 추세
종가
$237.77
시가
$237.97
고가
$239.37
저가
$236.16
30초 브리핑
RMD 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 49%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 18.2배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 0.8배
거래량은 최근 평균 범위입니다.
2026-10-29
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Aug 31, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
RMD 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Aug 31, 2026
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
9001 Spectrum Center Boulevard · San Diego, CA, United States · 직원 11,370명
시가총액
$34.67B
Trailing P/E
23.0
최근 12개월 이익 기준
Forward P/E
18.2
이익 증가 기대 반영
EPS (TTM)
$10.43
배당 수익률
1.10%
배당성향
23.0%
베타
0.75
시장보다 방어적
ROE
24.3%
P/B
5.26
EV/EBITDA
16.2
52주 범위
$180.27 – $284.87
현재 위치 49%
거래량
925.8K
20일 평균 1.09M · 0.8배
애널리스트 의견
매수 37%
총 19명 · 0m
DITM LEAPS Analysis
RMD 장기 DITM 콜옵션을 진입 적합도 순으로 비교
해당 종목의 옵션 데이터가 없습니다.
재무제표
RMD 연간 손익·현금흐름·재무상태
매출 성장률
+9.8%
최근 연간 YoY
EPS 성장률
—
최근 연간 YoY
영업이익률
32.7%
최근 연간
FCF 마진
32.1%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $5.15B+9.8% | $4.69B+10.9% | $4.22B+18.0% | $3.58B |
| 매출총이익 | $3.05B+15.1% | $2.66B+12.7% | $2.36B+16.4% | $2.02B |
| 영업이익 | $1.69B+21.8% | $1.38B+20.1% | $1.15B+15.0% | $1.00B |
| 순이익 | $1.40B+37.2% | $1.02B+13.7% | $897.56M+15.2% | $779.44M |
| 희석 EPS | — | $6.92+13.6% | $6.09+14.9% | $5.30 |
| EBITDA | $1.92B+20.0% | $1.60B+18.6% | $1.35B+14.7% | $1.18B |
| 영업현금흐름 | $1.75B+25.0% | $1.40B+102.1% | $693.30M+97.4% | $351.15M |
| 잉여현금흐름 | $1.65B+28.3% | $1.29B+130.0% | $559.30M+186.7% | $195.11M |
| 총자산 | $8.17B+18.9% | $6.87B+1.8% | $6.75B+32.5% | $5.10B |
| 총부채 | $851.81M-2.5% | $873.93M-44.7% | $1.58B+72.2% | $917.55M |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
RMD 실적·배당 일정
매출 하단
$1.36B
EPS 하단
$2.62
매출 상단
$1.42B
배당 지급일
2026-09-24
D-23
실적 발표일
2026-10-29
D-58
EPS 상단
$2.78
매출 컨센서스
$1.39B
EPS 컨센서스
$2.69
배당락일
2026-08-20
12일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Aug 20, 2026 | $0.6600 |
| May 14, 2026 | $0.6000 |
| Feb 12, 2026 | $0.6000 |
| Nov 13, 2025 | $0.6000 |
| Aug 14, 2025 | $0.6000 |
| May 8, 2025 | $0.5300 |
| Feb 13, 2025 | $0.5300 |
| Nov 7, 2024 | $0.5300 |
뉴스
RMD 관련 최신 기사
일반2 S&P 500 Stocks with Promising Prospects and 1 We Ignore
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
StockStory · Aug 27, 2026
제품·기술ResMed Stock: Analyst Estimates & Ratings
Although ResMed has underperformed the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Barchart · Aug 25, 2026
실적ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, which closed June 30, 2026, revenue grew 10%, and free cash flow topped $1.6 billion. The company also […]
Insider Monkey · Aug 17, 2026
실적The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call
ResMed’s second quarter saw steady revenue growth, but the market responded negatively as the company’s operating margin declined year over year. Management attributed the margin compression primarily to higher R&D and supply chain costs amid inflation, despite continued demand for sleep devices and masks. CEO Mick Farrell pointed to ongoing investments in innovation and supply chain efficiency as both a necessity and a source of margin challenges. Additionally, ResMed took a $42 million charge
StockStory · Aug 15, 2026
실적ResMed (RMD) Q4 2026 Earnings Call Transcript
Farrell discusses strategic divestitures, capital returns, and AI digital health expansion.
Motley Fool · Aug 14, 2026
제품·기술ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook
ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading at a discount to what the underlying cash flows may justify. ResMed has returned 26.3% over the past 3 years, which suggests that longer term holders have still seen gains despite the recent share price weakness. Recent pressure around a softer outlook and suspended ventilator sales can weigh on sentiment, while...
Simply Wall St. · Aug 12, 2026
- 실적
Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?
In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions share buyback program. At the same time, management issued a softer fiscal 2027 outlook tied to suspended ventilator sales after an FDA Class 1 recall and ongoing cost pressures, sharpening investor focus on how resilient ResMed’s broader sleep-health and...
Simply Wall St. · Aug 12, 2026
실적Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.
Zacks · Aug 11, 2026
- 일반
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen's steep sales-multiple discount, improving margins and firm international demand clash with U.S. sales and rental weakness.
Zacks · Aug 11, 2026
- 제품·기술
Resmed’s stock falls by 7% on soft FY27 outlook
Resmed highlighted that factors including suspended ventilator sales and ongoing macro uncertainty had contributed to its tempered FY27 outlook.
Medical Device Network · Aug 10, 2026
홀더
RMD 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
71.5%
기관 보유 (유동주식)
71.9%
내부자 보유
0.5%
기관 수
1,357
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 12.32M | $2.96B | 8.5% | 1.8% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 9.47M | $2.28B | 6.6% | 0.1% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 7.91M | $1.90B | 5.5% | 0.6% | Jun 30, 2026 |
| State Street Corporation | 6.68M | $1.61B | 4.6% | 0.6% | Jun 30, 2026 |
| Geode Capital Management, LLC | 4.35M | $1.05B | 3.0% | -0.0% | Jun 30, 2026 |
| Bank Of New York Mellon Corporation | 4.20M | $1.01B | 2.9% | -14.8% | Jun 30, 2026 |
| First Trust Advisors LP | 2.28M | $547.64M | 1.6% | 48.2% | Jun 30, 2026 |
| Invesco Ltd. | 2.06M | $495.94M | 1.4% | 5.5% | Jun 30, 2026 |
| Morgan Stanley | 1.93M | $463.58M | 1.3% | -28.2% | Jun 30, 2026 |
| Northern Trust Corporation | 1.70M | $407.76M | 1.2% | -1.7% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.